Clinical Development Risk Assessment in Oncology

This technical report outlines the evolving landscape of clinical development risk assessment in biopharmaceutical research and development, particularly in oncology. It discusses the limitations of traditional benchmark studies, which often provide a high-level view of development risk without addressing the complexities of modern drug development. The report identifies three key blind spots in current benchmarking practices: the oversimplification of therapeutic areas, the variability in risk profiles across different development phases, and the increasing importance of differentiation against standards of care. The analysis emphasizes that understanding where risk resides is crucial for making informed investment decisions. It highlights the need for program-level benchmarks that reveal the nuances of risk distribution, particularly as development costs rise. The report concludes that future competitive advantage will depend on the ability to measure and interpret risk more effectively, moving beyond average success rates to understand the factors that drive outcomes in drug development.